Company Overview of Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also include antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic inte...
Glenpointe Centre East
300 Frank West Burr Boulevard
Teaneck, NJ 07666
Key Executives for Phibro Animal Health Corporation
Chairman, Chief Executive Officer, President and Member of Compensation Committee
Total Annual Compensation: $2.5M
Chief Financial Officer
Total Annual Compensation: $664.7K
Chief Operating Officer
Total Annual Compensation: $652.7K
Compensation as of Fiscal Year 2016.
Phibro Animal Health Corporation Key Developments
Phibro Animal Mulls Acquisitions
Feb 7 17
Phibro Animal Health Corporation (NasdaqGM:PAHC) intends to pursue acquisitions. "In order that we can buy more reasonably, it causes us to work a lot harder. But we remain interested in growing the business both organically as well as by acquisition," Jack Bendheim, President and Chief Financial Officer, said.
Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 22, 2017
Feb 6 17
On February 6, 2017, Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on March 22, 2017, to stockholders of record at the close of business on March 1, 2017.
Phibro Animal Health Corporation Reports Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2016; Provides Earnings Guidance for the Fiscal Year 2017
Feb 6 17
Phibro Animal Health Corporation reported consolidated earnings results for second quarter and six months ended December 31, 2016. For the quarter, the company reported net sales of $191.6 million against $191.8 million a year ago. Operating income was $22.6 million against $22.6 million a year ago. Income before income taxes was $19.3 million against $16.1 million a year ago. Net income was $13.4 million or $0.34 per basic and diluted share against $30.2 million or $0.75 per diluted share a year ago. The decrease was a result of the factors described above, including an $18.8 million income tax benefit in the prior year period, partially offset by a $3.1 million favorable change in foreign currency (gains) losses, net. EBITDA was $29.6 million against $25.5 million a year ago. Adjusted EBITDA was $31.2 million against $28.4 million a year ago. Adjusted net income was $15.4 million against $14.7 million a year ago. Net cash provided by operating activities was $26.3 million against $8.0 million a year ago. Capital expenditures were $4.7 million against $9.6 million a year ago. Adjusted diluted EPS of $0.39, an increase of $0.02, or 5%.
For the six months, the company reported net sales of $379.6 million against $378.9 million a year ago. Operating income was $44.4 million against $44.5 million a year ago. Income before income taxes was $36.9 million against $39.6 million a year ago. Net income was $25.6 million or $0.64 per diluted share against $48.9 million or $1.22 per diluted share a year ago. EBITDA was $57.4 million against $58.2 million a year ago. Adjusted EBITDA was $61.0 million against $56.1 million a year ago. Adjusted net income was $30.0 million against $28.5 million a year ago. Net cash provided by operating activities was $47.7 million against $5.6 million a year ago. Capital expenditures were $10.6 million against $17.7 million a year ago.
For the fiscal year 2017, the company expects net sales to be from $750 million to $770 million, adjusted EBITDA to be from $116 million to $120 million, operating income to be from $95 million to $99 million, income before income taxes to be from $78 million to $82 million, net income to be from $55 million to $58 million and net income per diluted share to be from $1.38 to $1.45.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|